Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study

NCT02324387 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02324387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02324387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study
Lead sponsor
M.D. Anderson Cancer Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 15, 2015
Completion date
March 31, 2028
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer